← back to search

Towia A. Libermann

Beth Israel Deaconess Medical Center · US
Area of research
Critical Care and Intensive Care Medicine · Cancer Research
Research interest
Research interests include Intensive Care Unit Cognitive Disorders, NF-κB Signaling Pathways, Pharmacogenetics and Drug Metabolism, and Computational Drug Discovery Methods.
h-index
80
citations
35,859
works
450
NIH funding
primary concept
email

Recent publications

Proteomic Analysis Identifies Novel Plasma Biomarkers in Patients With Vestibular Schwannoma
Otology & Neurotology 2025cited by 0position: middledoi
Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction–associated steatohepatitis
Hepatology Communications 2024cited by 10position: lastdoi
DCUN1D1 Is an Essential Regulator of Prostate Cancer Proliferation and Tumour Growth That Acts through Neddylation of Cullin 1, 3, 4A and 5 and Deregulation of Wnt/Catenin Pathway
Cells 2023cited by 13position: middledoi
Dietary inflammatory and insulinemic potential, risk of hepatocellular carcinoma, and chronic liver disease mortality
JNCI Cancer Spectrum 2023cited by 11position: middledoi
High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma
Cancers 2023cited by 8position: middledoi
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
Frontiers in Oncology 2021cited by 60position: middledoi
The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
Cancers 2021cited by 59position: middledoi
Inflammatory metabolic profile of South African patients with prostate cancer
Cancer & Metabolism 2021cited by 26position: middledoi
Placenta accreta spectrum: biomarker discovery using plasma proteomics
American Journal of Obstetrics and Gynecology 2020cited by 88position: middledoi
Exosome swarms eliminate airway pathogens and provide passive epithelial immunoprotection through nitric oxide
Journal of Allergy and Clinical Immunology 2018cited by 60position: middledoi
Detecting Microbial Dysbiosis Associated with Pediatric Crohn Disease Despite the High Variability of the Gut Microbiota
Cell Reports 2016cited by 60position: middledoi
Relaxation Response Induces Temporal Transcriptome Changes in Energy Metabolism, Insulin Secretion and Inflammatory Pathways
PLoS ONE 2013cited by 313position: lastdoi
Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4
The Journal of Experimental Medicine 2012cited by 624position: middledoi
A metabolic prosurvival role for PML in breast cancer
Journal of Clinical Investigation 2012cited by 271position: middledoi
P02.117. Genomic expression changes underlying mind-body practices
BMC Complementary and Alternative Medicine 2012cited by 57position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Manoj Bhasin · Emory University5 papers (2012–2023)Simon T. Dillon · Boston Medical Center4 papers (2012–2024) · 3 papers (2016–2024)Nick Pavlakis · University of Sydney2 papers (2021–2021)Susan Carroll · University College Cork2 papers (2021–2021)George Hruby · The University of Sydney2 papers (2021–2021)Mark Stevens · Australian National University2 papers (2021–2021)Xuehong Zhang · Harvard University2 papers (2023–2024)Detlef Schuppan · Johannes Gutenberg University Mainz2 papers (2012–2023)David S. Rosenthal · Palo Alto University2 papers (2021–2021)Xuesong Gu · Anhui Medical University2 papers (2023–2024) · 2 papers (2012–2013) · 2 papers (2012–2013)Marita Morgia · Royal North Shore Hospital2 papers (2021–2021)Gillian Lamoury · The University of Sydney2 papers (2021–2021)Brian Corless · Royal North Shore Hospital2 papers (2021–2021)Jeffery A. Dusek · University of Alabama at Birmingham2 papers (2012–2013)Michael Back · The University of Sydney2 papers (2021–2021)Thomas Eade · The University of Sydney2 papers (2021–2021)Byeongsang Oh · The University of Sydney2 papers (2021–2021)